← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Nanotherapeutics, Inc.
Alachua, FL
$39,473,255
Total funding
13
Grants
Funding over time
peak $6.7M · FY2005–24$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$39,473,255 · 13
By mechanism
N01$34,080,240 · 6
R44$3,571,476 · 1
R01$812,118 · 1
R43$794,761 · 3
N44$116,660 · 1
N43$98,000 · 1
Investigators at Nanotherapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
CIDOFOVIR FORMULATION FOR POSTEXPOSURE TREATMENT$6,431,950
N01 · FY2010 · AI
CIDOFOVIR FORMULATION FOR POSTEXPOSURE TREATMENT$6,420,503
N01 · FY2009 · AI
Advanced Development of Medical Countermeasures for Infectious Diseases$4,300,537
N01 · FY2023 · AI
Advanced Development of Medical Countermeasures for Infectious Diseases$4,233,500
N01 · FY2021 · AI
Advanced Development of Medical Countermeasures for Infectious Diseases$3,353,569
N01 · FY2019 · AI
Production of monoclonal antibody-based therapeutics for botulism$2,049,872
N01 · FY2016 · AI
Advanced Development of Medical Countermeasures for Infectious Diseases$1,776,307
N01 · FY2020 · AI
Advanced Development of Medical Countermeasures for Infectious Diseases$1,223,182
N01 · FY2024 · AI
Prophylaxis and Treatment of Aerosolized Pneumonic Plague and Tularemia$1,000,000
N01 · FY2008 · AI
GelVac Stable, Dry-Powder Nasal Recombinant VLP-Based Bivalent Norovirus Vaccine$997,966
R44 · FY2015 · AI
GelVac Stable, Dry-Powder Nasal Recombinant VLP-Based Bivalent Norovirus Vaccine$997,804
R44 · FY2014 · AI
GelVac Stable, Dry-Powder Nasal Recombinant VLP-Based Bivalent Norovirus Vaccine$996,995
R44 · FY2013 · AI
Development of Improved DTPA for Radionuclide Chelation$949,473
N01 · FY2008 · AI
Inhaled Aminoglycoside Formulafor Plague and Tularemia$812,118
R01 · FY2005 · AI
TASK B1: STABILITY TESTING OF THERAPEUTICS FOR BOTULISM$565,110
N01 · FY2017 · AI
Task C2: Analytical Method, Process Development and Manufacturing for Therapeutics$485,288
N01 · FY2023 · AI
Task C2: Analytical Method, Process Development and Manufacturing for Therapeutics$314,492
N01 · FY2024 · AI
Development of A Synthetic Typhoid Fever Vaccine as A Substitution of Vi Vaccine$299,614
R43 · FY2010 · AI
Development of A Synthetic Typhoid Fever Vaccine as A Substitution of Vi Vaccine$296,331
R43 · FY2011 · AI
GelVac Stable, Dry-Powder Nasal Recombinant VLP-Based Bivalent Norovirus Vaccine$289,356
R44 · FY2012 · AI